Primary Hyperaldosteronism and Ischemia-reperfusion Injury

计划入组 40 人 · 首次发布于 2013 年 11 月 7 日

Antinociceptive Modalities on Ischemia Reperfusion Injury

计划入组 142 人 · 首次发布于 2013 年 8 月 30 日

Arginase Inhibition in Ischemia-reperfusion Injury

计划入组 24 人 · 首次发布于 2013 年 12 月 12 日

MFH-244

myristic acid conjugated PKC beta II peptide inhibitor (ischemia and reperfusion injury)

SERCA2 inhibitor (ischemic reperfusion injury)

BRUNEL UNIVERSITY LONDON

United Kingdom

Manchester Metropolitan University

United Kingdom

NervGen Pharma

Arch Biopartners Doses First Patient in Canada for Phase II Trial of LSALT Peptide in Cardiac Surgery-Associated Acute Kidney Injury

Arch Biopartners' LSALT Peptide Phase II Trial Approved for Cardiac Surgery-Associated Acute Kidney Injury

Arch Biopartners Initiates Phase II Trial of LSALT Peptide for Cardiac Surgery-Associated Acute Kidney Injury